Leukemia & Lymphoma Society: Pacific Northwest Region’s Post

In the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumors, CD5-negative B-cell prolymphocytic leukemia has been replaced. The new entity is known as splenic B-cell lymphoma/leukemia with prominent nucleoli. What are your thoughts on this update?

🚨 Did you know? Diffuse large b-cell lymphoma, the most common type of non-Hodgkin’s lymphoma in the US, affects 30,000 new patients each year. With a relapse rate of up to 40% within two years, ongoing advancements in treatment are critical. ✨ Good news is on the horizon: #DLBCL is curable in 60-70% of cases with initial therapy. 🤝 In ACCC’s partnership with The Leukemia and Lymphoma Society we have produced https://bit.ly/3WPkJe5, a guide designed to hone communication, clarify treatment expectations, and help boost patient confidence through shared decision-making. 🔗 https://bit.ly/3wMWJgT Access the guide, a communication road map, and resource library to transform DLBCL treatment and patient engagement. Will you be at #ASCO24? Come visit ACCC’s booth, we’ll see you in Chicago! #LymphomaAwareness #HealthCommunication

Analyze in a different light! Join us in this webinar series on leukemia and lymphoma analysis

The #BloodCancer landscape continues to evolve through scientific innovations that not only clinically benefit patients, but also strengthen their care and quality of life.     Explore the emerging themes this year to watch for with The Leukemia & Lymphoma Society: https://e.lilly/3P0Rm3F  

This unique case underscores the challenges in diagnosing and managing ocular manifestations of mantle cell lymphoma, a rare and usually high-grade type of non-Hodgkin lymphoma. https://lnkd.in/eG_JKjeg #Ophthalmology #ClinicalResearch #OcularOncology

September is Leukemia & Lymphoma Awareness Month. 💙 For those facing these challenges, ongoing follow-up and treatment management is crucial. Knowing the specific type of leukemia or lymphoma helps tailor the best care and predict outcomes. We're here to support you every step of the way! 📞702.380.8300 🔗Link in bio #ProCareHospice #LeukemiaAwareness #LymphomaAwareness #LasVegasHospice #LasVegasCare

Approximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma, or myeloma, while 40.5% of the US population will be diagnosed with cancer at some point in their lifetime. In partnership with The Leukemia & Lymphoma Society, Sharecare Life Sciences’ Patient Experience Lab surveyed our consumer and HCP audiences about their knowledge and experiences with cancer survivorship. Check out the full results at the link below.  https://lnkd.in/eCPzPdtf #SurvivorAwareness #SharecareZeroPartyData

There was a lot of amazing research presented at ASH this year around the tremendous progress that's been made using OGM for leukemia, lymphoma, and myeloma (https://lnkd.in/eZgTk8aV):

Metabolic Regulation of Lymphoma Development: #AACRFellows Tak W. Mak will address this topic in a keynote lecture at the Fourth AACR International Meeting on Advances in Malignant Lymphoma (June 19-22, Philadelphia). Learn more: https://bit.ly/3IOXuIW #AACRlymph24

Establishing rapport, building trust, and empowering patients with cancer are important outcomes of effective patient-provider communication. Learn more about key insights derived from ACCC and The Leukemia & Lymphoma Society focus groups in the most recent Oncology Issues: https://bit.ly/4ddUy5Q.